Patents by Inventor Stephen T. Isaacs
Stephen T. Isaacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6686480Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: June 3, 2002Date of Patent: February 3, 2004Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6680025Abstract: A device containing a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.Type: GrantFiled: September 6, 2002Date of Patent: January 20, 2004Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Publication number: 20030185804Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: ApplicationFiled: August 6, 2002Publication date: October 2, 2003Applicant: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Publication number: 20030170141Abstract: A device comprising a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.Type: ApplicationFiled: September 6, 2002Publication date: September 11, 2003Applicant: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Publication number: 20030105339Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: ApplicationFiled: June 3, 2002Publication date: June 5, 2003Applicant: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6503699Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: August 16, 1999Date of Patent: January 7, 2003Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6469052Abstract: The present invention includes compositions comprising new psoralens with either a 4 ′, or 5 ′primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.Type: GrantFiled: January 22, 2001Date of Patent: October 22, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6461567Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: June 11, 2001Date of Patent: October 8, 2002Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6420570Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: January 22, 2001Date of Patent: July 16, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Publication number: 20020044885Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: ApplicationFiled: June 11, 2001Publication date: April 18, 2002Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Publication number: 20020006393Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: ApplicationFiled: January 22, 2001Publication date: January 17, 2002Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6258319Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: September 4, 1998Date of Patent: July 10, 2001Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6218100Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5′-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.Type: GrantFiled: July 24, 1997Date of Patent: April 17, 2001Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6194139Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: September 28, 1999Date of Patent: February 27, 2001Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6017691Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: February 9, 1996Date of Patent: January 25, 2000Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6004742Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic add of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular compounds with primary aminoalkyl substitutions on the 4' or 5' positions of psoralen are used to inactivate pathogens in blood products such as platelets.Type: GrantFiled: November 3, 1997Date of Patent: December 21, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6004741Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.Type: GrantFiled: October 23, 1997Date of Patent: December 21, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5972593Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: March 30, 1998Date of Patent: October 26, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 5871900Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.Type: GrantFiled: November 7, 1997Date of Patent: February 16, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5854967Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: February 25, 1997Date of Patent: December 29, 1998Assignee: Cerus CorporationInventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs